BYQLOVI approved for post‑op inflammation

BYQLOVI is an eye-drop steroid for the sore, inflamed period after eye surgery — especially cataract surgery, where the whole recovery plan can hinge on a patient actually using drops correctly at home. That sounds routine, but it is a real bottleneck in ophthalmology. Patients get multiple bottles, multiple schedules, and a lot of room for missed doses. The news here is that BYQLOVI, a clobetasol propionate ophthalmic suspension sold under that brand name, now has FDA approval for post-operative inflammation and pain following ocular surgery. (accessdata.fda.gov) ### What exactly is BYQLOVI? BYQLOVI is clobetasol propionate ophthalmic suspension 0.05% — a topical corticosteroid used in the eye. Clobetasol is a very potent steroid name that many clinicians already know from dermatology, but this is an ophthalmic suspension built for eye use, not a repurposed skin product. The approved label positions it as a post-surgical anti-inflammatory and pain treatment after ocular surgery. (accessdata.fda.gov) ### Why does cataract surgery make this relevant? Cataract surgery is one of the most common operations in medicine, and the surgery itself is usually quick. The annoying part comes after — inflammation, discomfort, and the need to keep the eye quiet while it heals. That is why post-op steroid drops are such a big category. Harrow, which took U.S. commercial rights (accessdata.fda.gov)., which gives a sense of the scale. (ophthalmologytimes.com) ### What does the dosing look like? The regimen is straightforward: one drop in the affected eye twice a day, starting the day after surgery and continuing through the first 2 weeks after the operation. That simplicity matters more than it sounds. In post-cataract care, every extra bottle and every extra daily dose raises the odds that someone gets off schedule. A twice-daily plan is easier for both surgeons and patients to work with. (accessdata.fda.gov) ### What evidence got it over the line? The FDA label points to two multicenter, randomized, double-masked, vehicle-controlled trials in patients who had at least 10 anterior-chamber cells after cataract surgery. Those studies enrolled 366 patients on the drug and 382 on vehicle. So while the indication is broader — post-operative inflammation and pain after ocular (accessdata.fda.gov)y patients. (accessdata.fda.gov) ### Why are people calling this different? Part of the pitch is that BYQLOVI is the first FDA-approved ophthalmic clobetasol product and, when it was cleared in March 2024, it was described as the first new steroid on the U.S. ophthalmic market in more than 15 years. Formosa also built it with its APNT nanoparticle formulation platform, which is meant to keep the su(accessdata.fda.gov)teroid,” but “a potent steroid in a formulation designed to behave predictably in the bottle.” (europe.ophthalmologytimes.com) ### What is the catch? It is still a steroid, so the usual steroid eye warnings come with it. The label flags increased intraocular pressure, cataract risk with prolonged use, delayed healing after cataract surgery, and the possibility of masking or worsening infection. It is also contraindicated in certain viral, fungal, and mycobacterial eye diseases. So this is not a casual over-the-counter comfort drop — it is a physician-managed post-op drug. (accessdata.fda.gov) ### How does this fit the bigger shift in cataract aftercare? The broader trend is a search for less fragile recovery plans. Some companies are still trying to move treatment into the operating room itself, so patients do less at home. Harrow’s own TRIESENCE program, for example, is being studied in 2026 as a sustained anti-inflammatory option after cataract surgery(accessdata.fda.gov)problem — it is still a drop, but one designed to be potent and relatively simple to use. (ophthalmologytimes.com) ### Bottom line BYQLOVI matters because cataract recovery is still full of small failure points, and post-op inflammation control is one of the biggest. This approval adds a new branded steroid option with a simple twice-daily schedule and cataract-trial backing. Whether it changes practice widely will come down to the usual things — surgeon comfort, pricing, access, and how the real-world safety and convenience story holds up.